Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma

Journal of Urology

Volumn 181, Issue 5, 2009, Pages 2044-2051

  Margulis, Vitaly ^a   McDonald, Michelle ^a   Tamboli, Pheroze ^a   Swanson, David A ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

carcinoma; kidney; mortality; neoplasm recurrence; nephrectomy; renal cell

Indexed keywords

ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; PERIOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RISK ASSESSMENT; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 64049097453     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.043     Document Type: Article

References (20)

1. Esrig D., Ahlering T.E., Lieskovsky G., and Skinner D.G. Experience with fossa recurrence of renal cell carcinoma. J Urol 147 (1992) 1491
2. Tanguay S., Pisters L.L., Lawrence D.D., and Dinney C.P. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 155 (1996) 26
3. Itano N.B., Blute M.L., Spotts B., and Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164 (2000) 322
4. Schrodter S., Hakenberg O.W., Manseck A., Leike S., and Wirth M.P. Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 167 (2002) 1630
5. Bruno II J.J., Snyder M.E., Motzer R.J., and Russo P. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 97 (2006) 933
6. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., Bex A., de Gast G., Haanen J.B., et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14 (2008) 2431
7. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427
8. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115
9. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125
10. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271
11. Greene F.L. AJCC Cancer Staging Manual. American Joint Committee on Cancer. American Cancer Society. 6th ed. (2002), Springer-Verlag, New York pp xiv and 421.
12. Eble J.N. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization (2004), IARC Press, Lyon Oxford 359
13. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23 (2005) 1028
14. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 7 (2007) 73
15. Wood C.G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 13 (2007) 697s
16. Karakiewicz P.I., Suardi N., Jeldres C., Audet P., Ghosn P., Patard J.J., et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53 (2008) 845
17. Shuch B., Riggs S.B., Larochelle J.C., Kabbinavar F.F., Avakian R., Pantuck A.J., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008)
18. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454
19. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., Malhi S., Wood L., Elson P., et al. Validation and extension of the Memorial-Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832
20. Margulis V., Matin S.F., Tannir N., Tamboli P., Swanson D.A., Jonasch E., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180 (2008) 94